{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:47:25Z","timestamp":1792716445641,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ahj.2024.10.004","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T06:14:16Z","timestamp":1728108856000},"page":"9-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Dual antiplatelet therapy duration and stent type in patients with high bleeding risk: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"279","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5356-9477","authenticated-orcid":false,"given":"Tetsuya","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2487-8366","authenticated-orcid":false,"given":"Toshiki","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Fujisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaveh","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisato","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Wiley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sripal","family":"Bangalore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2024.10.004_bib0001","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2024.10.004_bib0002","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.10.004_bib0003","first-page":"3238","article-title":"Antithrombotic therapy in the elderly: expert position paper of the European society of cardiology working group on thrombosis","volume":"36","author":"Andreotti","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.10.004_bib0004","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1161\/CIRCULATIONAHA.117.032180","article-title":"Comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization","volume":"137","author":"Savonitto","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.10.004_bib0005","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacc.2018.11.048","article-title":"Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting","volume":"73","author":"Costa","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.10.004_bib0006","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.10.004_bib0007","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jacc.2021.09.005","article-title":"2021 ACC\/AHA\/SCAI Guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"79","author":"Lawton","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.10.004_bib0008","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.10.004_bib0009","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"45","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.10.004_bib0010","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the optimize randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"Jama"},{"key":"10.1016\/j.ahj.2024.10.004_bib0011","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: the reset trial (real safety and efficacy of 3-month dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.10.004_bib0012","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jacasi.2022.09.011","article-title":"Clopidogrel monotherapy after 1-month DAPT in patients with high bleeding risk or complex PCI","volume":"3","author":"Yamamoto","year":"2023","journal-title":"JACC Asia"},{"key":"10.1016\/j.ahj.2024.10.004_bib0013","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/eurheartj\/ehac706","article-title":"Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials","volume":"44","author":"Costa","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.10.004_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2022.04.004","article-title":"Dual antiplatelet therapy duration after percutaneous coronary intervention using drug eluting stents in high bleeding risk patients: a systematic review and meta-analysis","volume":"250","author":"Garg","year":"2022","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2024.10.004_bib0015","first-page":"1455","article-title":"Response to Camenzind et al: commentary","volume":"115","author":"Serruys","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.10.004_bib0016","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jcin.2013.07.009","article-title":"5-year results of a randomized comparison of XIENCE v everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial Clinical Evaluation of the XIENCE v Everolimus Eluting Coronary Stent System in the Treatment of Patient","volume":"6","author":"Gada","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2024.10.004_bib0017","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ccd.28045","article-title":"Meta-analysis of drug eluting stents compared with bare metal stents in high bleeding risk patients undergoing percutaneous coronary interventions","volume":"94","author":"Neupane","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2024.10.004_bib0018","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(17)32713-7","article-title":"Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial","volume":"391","author":"Varenne","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2024.10.004_bib0019","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free drug-coated coronary stents in patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.10.004_bib0020","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.jcin.2021.06.003","article-title":"1-Month dual-antiplatelet therapy followed by aspirin monotherapy after polymer-free drug-coated stent implantation: one-month DAPT trial","volume":"14","author":"Hong","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2024.10.004_bib0021","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1056\/NEJMoa1910021","article-title":"Polymer-based or polymer-free stents in patients at high bleeding risk","volume":"382","author":"Windecker","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.10.004_bib0022","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/CIRCULATIONAHA.123.065448","article-title":"Biodegradable-polymer or durable-polymer stents in patients at high bleeding risk: a randomized, open-label clinical trial","volume":"148","author":"Valgimigli","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.10.004_bib0023","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2024.10.004_bib0024","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1161\/CIRCULATIONAHA.117.029289","article-title":"Standardized end point definitions for coronary intervention trials: the academic research consortium-2 consensus document","volume":"137","author":"Garcia-Garcia","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.10.004_bib0025","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2024.10.004_bib0026","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2024.10.004_bib0027","doi-asserted-by":"crossref","first-page":"E990","DOI":"10.4244\/EIJ-D-19-00539","article-title":"Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial)","volume":"15","author":"de Luca","year":"2019","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ahj.2024.10.004_bib0028","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jcin.2015.11.015","article-title":"Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention? a pre-specified analysis from the ZEUS trial","volume":"9","author":"Ariotti","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2024.10.004_bib0029","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4070\/kcj.2021.0321","article-title":"Ticagrelor monotherapy after 3-month dual antiplatelet therapy in acute coronary syndrome by high bleeding risk: the subanalysis from the TICO trial","volume":"52","author":"Lee","year":"2022","journal-title":"Korean Circ J"},{"key":"10.1016\/j.ahj.2024.10.004_bib0030","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.10.004_bib0031","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA - J Am Med Assoc"},{"key":"10.1016\/j.ahj.2024.10.004_bib0032","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1093\/eurheartj\/ehab702","article-title":"Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR","volume":"42","author":"Escaned","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.10.004_bib0033","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.4244\/EIJ-D-20-00187","article-title":"A prospective, multicentre, randomised, open-label trial to compare the efficacy and safety of clopidogrel versus ticagrelor in stabilised patients with acute myocardial infarction after percutaneous coronary intervention: rationale and design of the TALO","volume":"16","author":"Park","year":"2021","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ahj.2024.10.004_bib0034","first-page":"1","article-title":"Clinical usefulness of PRECISE-DAPT score for predicting bleeding events in patients with acute coronary syndrome undergoing percutaneous coronary intervention: an analysis from the SMART-DATE randomized trial","volume":"13","author":"Choi","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2024.10.004_bib0035","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1161\/CIRCULATIONAHA.119.040241","article-title":"Randomized comparison of the polymer-free biolimus-coated biofreedom stent with the ultrathin strut biodegradable polymer sirolimus-eluting orsiro stent in an all-comers population treated with percutaneous coronary intervention","volume":"141","author":"Jensen","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.10.004_bib0036","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/ehjqcco\/qcy036","article-title":"A meta-analysis of randomized controlled trials to compare long-term clinical outcomes of bioabsorbable polymer and durable polymer drug-eluting stents","volume":"5","author":"Mridha","year":"2019","journal-title":"Eur Hear J - Qual Care Clin Outcomes"},{"key":"10.1016\/j.ahj.2024.10.004_bib0037","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jcin.2016.12.002","article-title":"Meta-analysis of randomized clinical trials comparing biodegradable polymer drug-eluting stent to second-generation durable polymer drug-eluting stents","volume":"10","author":"El-Hayek","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2024.10.004_bib0038","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.jcin.2019.04.046","article-title":"Everolimus-eluting biodegradable polymer versus everolimus-eluting durable polymer stent for coronary revascularization in routine clinical practice","volume":"12","author":"Zanchin","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2024.10.004_bib0039","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1161\/CIRCULATIONAHA.120.051700","article-title":"Durable polymer versus biodegradable polymer drug-eluting stents after percutaneous coronary intervention in patients with acute coronary syndrome","volume":"143","author":"Kim","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.10.004_bib0040","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijcard.2021.06.034","article-title":"Acute thrombogenicity of fluoropolymer coated stents versus competitive drug-eluting stents under single antiplatelet therapy","volume":"338","author":"Sato","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2024.10.004_bib0041","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.4244\/EIJ-D-17-00728","article-title":"Acute thrombogenicity of fluoropolymer-coated versus biodegradable and polymer-free stents","volume":"14","author":"Torii","year":"2019","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ahj.2024.10.004_bib0042","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.jcin.2019.06.006","article-title":"Acute thrombogenicity of SYNERGY drug-eluting stent: the \u201cBare Metal\u201d concern?","volume":"12","author":"Bangalore","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2024.10.004_bib0043","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.123.066720","article-title":"An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial","volume":"149","author":"Natsuaki","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.10.004_bib0044","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1016\/j.jcin.2023.08.014","article-title":"1- or 3-month DAPT in patients with HBR with or without oral anticoagulant therapy after PCI","volume":"16","author":"Valgimigli","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2024.10.004_bib0045","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1161\/CIRCULATIONAHA.118.034456","article-title":"Newer-generation ultrathin strut drug-eluting stents versus older second-generation thicker strut drug-eluting stents for coronary artery disease: meta-analysis of randomized trials","volume":"138","author":"Bangalore","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.10.004_bib0046","first-page":"1","article-title":"Comparison between ticagrelor and clopidogrel in myocardial infarction patients with high bleeding risk","volume":"9","author":"Tjerkaski","year":"2023","journal-title":"Eur Hear J - Cardiovasc Pharmacother"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324002667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324002667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T09:05:08Z","timestamp":1733130308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870324002667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":46,"alternative-id":["S0002870324002667"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2024.10.004","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual antiplatelet therapy duration and stent type in patients with high bleeding risk: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2024.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}